Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Kolomansky, Albert, Kaye, Irit, Ben-Califa, Nathalie, Gorodov, Anton, Awida, Zamzam, Sadovnic, Ofer, Ibrahim, Maria, Liron, Tamar, Hiram-Bab, Sahar, Oster, Howard S., Sarid, Nadav, Perry, Chava, Gabet, Yankel, Mittelman, Moshe, Neumann, Drorit
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604358/
https://ncbi.nlm.nih.gov/pubmed/33193330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.561294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados